Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2003
10/02/2003US20030186839 Medicinal compositions
10/02/2003US20030186838 Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders
10/02/2003US20030186419 Masp-3, a complement-fixing enzyme, and uses for it
10/02/2003US20030186415 Mutant possessing uracil phosphoribosyl transferase activity
10/02/2003US20030186406 Peptide capable of inducing immune response to human gastric cancer and agent for preventing or treating human gastric cancer, containing the peptide
10/02/2003US20030186383 Comprise nucleotide sequences coding growth factor polypeptide for diagnosing and treating autoimmune, cell proliferative, atherosclerotic, inflammatory and cancer disorders; tissue engineering; wound healing agents
10/02/2003US20030186381 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
10/02/2003US20030186337 Novel death associated proteins, and THAP1 and PAR4 pathways in apoptosis control
10/02/2003US20030186325 Method of screening for inhibitors of osteopontin
10/02/2003US20030186308 Prostacyclin-stimulating factor-2
10/02/2003US20030186264 Comprises enzymatic polypeptide for diagnosis and treatment of genetic disorders; drug screening; immunoassay; high throughput assay
10/02/2003US20030186232 Human and non-human primate homologues of Nkd protein, nucleic acid sequences encoding, and uses thereof
10/02/2003US20030185908 Monoamine oxidase (MAO) inhibitors and uses thereof
10/02/2003US20030185895 Spherical polymer particle (e.g., a polyvinyl acetal) having an internal reservoir region including large pores containing therapeutic agent and a metering region having fewer relatively large pores.
10/02/2003US20030185893 Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
10/02/2003US20030185891 Glycogen phosphorylase inhibitor
10/02/2003US20030185880 Glyburidge composition
10/02/2003US20030185873 Provides reversible local anesthesia when implanted or injected in a patient, and a non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia
10/02/2003US20030185864 Preventives or remedies for atopic dermatitis
10/02/2003US20030185831 Methods of treating cancer using an FPT inhibitor and antineoplastic
10/02/2003US20030185823 Arming of activated T cells with BiAbs increases the effective precursor frequency of CTL in the cancer patient.
10/02/2003US20030185818 Humanized antibody against cd18
10/02/2003US20030185815 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
10/02/2003US20030185802 DNA construct operably encoding a vascular endothelial growth factor receptor protein.
10/02/2003US20030185794 Such as a pleiotrophin or midkine molecule in a pharmaceutically acceptable carrier.
10/02/2003US20030185793 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same
10/02/2003US20030185791 TNF-derived peptides for use in treating oedema
10/02/2003US20030185789 Lipase inhibiting polymers
10/02/2003US20030185788 Guanidinium moieties that are either contiguous or spaced along a polymeric backbone, but are sufficiently removed from the backbone via tethers, to allow their interaction with a cell or tissue surface
10/02/2003US20030185786 Bis(polyoxyalkylene) fumarate; epidermal permeability barrier function enhancer, amphiregulin expression inhibitor, epidermal hyperproli- feration inhibitor, HB-EGF expression inducing agent, ameliorating agent for aged skin
10/02/2003CA2761440A1 Fredericamycin derivatives
10/02/2003CA2756798A1 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
10/02/2003CA2488161A1 Novel aminobenzamide derivative
10/02/2003CA2480471A1 A process for the extraction of anthocyanins from black rice and composition thereof
10/02/2003CA2480384A1 Phenanthridinones as parp inhibitors
10/02/2003CA2480335A1 Combined use of antitumor indolopyrrolocarbazole derivative and other antitumor agent
10/02/2003CA2480334A1 Hepatocurative effect of emblica officinalis on hepatotoxicity related to cytochrome p-450
10/02/2003CA2480096A1 Process for producing triterpene derivatives
10/02/2003CA2480039A1 Spiro derivatives and adhesion molecule inhibitors comprising the same as active ingredient
10/02/2003CA2480034A1 Antibody fusion proteins: effective adjuvants of protein vaccination
10/02/2003CA2480032A1 Use of ltb4 antagonists in veterinary medicine
10/02/2003CA2479908A1 Calcineurin activator
10/02/2003CA2479898A1 Novel .alpha.-amino-n-(diaminophosphinyl)lactam derivatives
10/02/2003CA2479887A1 Piperidine or 8-aza-bicyclo¬3.2.1|oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially ccr5)
10/02/2003CA2479881A1 Hif hydroxylase inhibitors
10/02/2003CA2479880A1 Combination comprising an hmg-coa reductase inhibittor and an insulin secretor enhancer or an insulin sensitizer
10/02/2003CA2479718A1 Analgesics for nasal administration
10/02/2003CA2479671A1 Combination of an aldosterone receptor antagonist and nicotinic acid for a nicotinic acid derivative
10/02/2003CA2479338A1 Substituted phenylacetic acids
10/02/2003CA2479279A1 Fused bicyclic pyridine derivative as tachykinin receptor antagonist
10/02/2003CA2479277A1 Fused bicyclic pyrimidine derivatives
10/02/2003CA2479256A1 Phosphate prodrugs of fluorooxindoles
10/02/2003CA2479254A1 Preventive or therapeutic agent for renal disease
10/02/2003CA2478913A1 Substituted chroman derivatives having cytochrome p450rai inhibitory activity
10/02/2003CA2478801A1 Method for administration of growth hormone via pulmonary delivery
10/02/2003CA2478330A1 Intraductal management of breast lesions involving therapeutic or diagnostic agents
10/02/2003CA2478327A1 Hgh (human growth hormone) formulations for pulmonary administration
10/02/2003CA2477812A1 A non-selective cation channel in neural cells and methods for treating brain swelling
10/02/2003CA2477771A1 Phthalimido derivatives as inhibitors of monoamine oxidase b
10/02/2003CA2477651A1 Kinase inhibitors
10/02/2003CA2474637A1 Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane nmda, 5ht3, and neuronal nicotinic receptor antagoni sts
10/02/2003CA2451516A1 Agent for preventing or treating diseases caused by enos expression
10/01/2003EP1348707A1 Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy
10/01/2003EP1348706A1 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
10/01/2003EP1348704A1 Indole derivatives as 5-HT2C antagonists, process for their preparation and pharmaceutical compositions containing them
10/01/2003EP1348701A1 (2,4-disubstituted-thiazol-5-yl) amine compounds as PDE7 inhibitors
10/01/2003EP1348434A1 Use of pyridyl amides as inhibitors of angiogenesis
10/01/2003EP1348433A1 Thiazol-2-yl-imine compounds as PDE-7 inhibitors
10/01/2003EP1348036A2 Protection against mycobacterial infections
10/01/2003EP1348029A2 Materials and methods relating to protein aggregation in neurodegenerative disease
10/01/2003EP1347992A2 Polymorphic bone morphogenetic protein 2
10/01/2003EP1347990A2 Peptide mit inhibierender aktivität zur produktion von stickstoffmonoxid
10/01/2003EP1347982A2 Spiro isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
10/01/2003EP1347980A1 Compounds specific to adenosine-a1,-a2a, and- a3-receptor and uses thereof
10/01/2003EP1347979A1 Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands
10/01/2003EP1347978A1 Novel substituted imidazotriazinones as pde ii-inhibitors
10/01/2003EP1347976A2 Tricyclic purine compounds and their analogs as inhibiotrs of cytokine signalling
10/01/2003EP1347975A1 Novel purine derivatives, preparation method and use as medicines
10/01/2003EP1347974A1 Aminotriazolopyridiine derivatives as adenosine receptor ligands
10/01/2003EP1347973A1 Pyrrolo (2.1-a) dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors
10/01/2003EP1347972A1 Pyrazolo 3,4-c]pyridines as gsk-3 inhibitors
10/01/2003EP1347971A1 Thiazolyl inhibitors of tec family tyrosine kinases
10/01/2003EP1347967A1 Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
10/01/2003EP1347966A1 Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
10/01/2003EP1347963A2 Benzofuran and benzothiophene derivatives as selective cox-2 inhibitors
10/01/2003EP1347783A1 Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units
10/01/2003EP1347779A2 Use of a triple combination comprising a 5ht3 antagonist, a 5ht4 agonist and a laxative for promoting intestinal lavage
10/01/2003EP1347778A1 Behavior chemotherapy
10/01/2003EP1347773A2 Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
10/01/2003EP1347768A1 Cosmetic and/or dermopharmaceutical preparations containing leaf extracts of the plant argania spinosa
10/01/2003EP1347767A1 Tahitian noni juice on cox-1 and cox-2 and tahitian noni juice as a selective cox-2 inhibitor
10/01/2003EP1347765A2 Dermatological formulations
10/01/2003EP1347762A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2)
10/01/2003EP1347761A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
10/01/2003EP1347752A2 Anti-proliferative drugs
10/01/2003EP1347751A2 Methods of treating bone cancer and the pain associated therewith using endothelin antagonists
10/01/2003EP1347746A1 Over-coated chewing gum formulations including tableted center
10/01/2003EP1206472B1 Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent
10/01/2003EP1202954B1 Novel aminobenzophenones
10/01/2003EP1202724B1 Method for treating chronic pain using mek inhibitors
1 ... 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 ... 1564